Mirataz® (mirtazapine transdermal ointment) is the only transdermal mirtazapine approved by the Food and Drug Administration (FDA) after undergoing rigorous testing to prove safety, quality, and efficacy. Compounded transdermal formulations of mirtazapine have not undergone the FDA approval process, and their quality, safety, and efficacy can not be guaranteed. bit.ly/2przgLX
Mirataz® is indicated for the management of weight loss in cats.
Important Safety Information Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application. The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information: bit.ly/2yU2Txg. ...
CVM Update describing FDA Dear Veterinarian Letter about the differences between FDA-approved Mirataz (mirtazapine transdermal ointment), an animal drug with demonstrated safety and effectiveness to manage undesired weight loss in cats, and compounded formulations of transdermal mirtazapine.